We believe the study of human health in real-world, everyday environments is necessary to advance knowledge and discovery.
We make this possible by providing customized body-worn monitoring and analysis solutions rooted in scientific foundations.
We enable the world’s best researchers to obtain the highest quality, real-world data and analyze it appropriately and accurately.
The founding team at VivoSense met and worked together at VivoMetrics, Inc., which manufactured and commercialized one of the first multichannel wearable sensors called LifeShirt. Applications for the LifeShirt (purchased by adidas in 2008) platform include aerospace research, infant monitoring, drug and device clinical trials (e.g. cough monitoring), and media/commercial research. The LifeShirt platform was supported using an analysis software known as VivoLogic. VivoSense was created to become the second-generation version of VivoLogic which would service ALL commercially available wearable sensors, many of which were predicated on the LifeShirt sensor.
The creation of VivoSense software was initially funded with a $1M grant from the US Navy which required software for the interrogation of physiological sensors placed directly on-body. From inception copies of VivoSense software were sold to academic researchers and not for profit companies that continue to provide academic validation and peer-reviewed publications using the software. VivoSense has subsequently grown to service the pharmaceutical clinical trials industry using the software as the environment in which new digital biomarkers are created.
" title="Dudley Tabakin "
>Dudley is CEO and co-founder of VivoSense and a fervent believer in “good data” over “big data” in the development of digital clinical measures from wearable sensor technology. He has a background in sports and gait biomechanics and more than 10 years experience in wearable sensor data analytics.
" title="Tanja Dowe "
>Tanja is the CEO of Debiopharm Innovation Fund, an evergreen fund investing in digital health companies that transform patient journeys and pharmaceutical R&D. Prior to joining Debiopharm, Tanja was the Managing Partner of Innomedica Ltd, a boutique strategy and transaction consulting company in life sciences, and a founder/CEO of a market research agency BioSolutions INT.
" title="Chris Garabedian "
>Chris founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund which supports early stage companies with Series A investments across biotech, medtech and healthtech.
" title="Lance Myers "
>Lance has 20+ years experience in digital health and has held multiple executive leadership positions over the course of his career. He was the Founding CEO of VivoSense from 2010 - 2014. Since 2017 he has served as the Head of Data Science at Verily Life Sciences and also leads a cardiovascular innovations business unit.
